odn 1018 Search Results


odn1018  (MedChemExpress)
93
MedChemExpress odn1018
a , BMDCs were incubated with 100 nM OVA peptide, diABZI + OVA or ABM5–OVA either carrier free or encapsulated in LNPs for 4 h. n = 3 biologically independent samples. b , c , BMDCs receiving 50 nM OVA peptide, ABM5–OVA or LNP-encapsulated ABM5–OVA for 4 h and then co-cultured with OT-I cells for 72 h. n = 3 biologically independent samples. All ABM5–OVA, ABD–S–OVA, OVA peptides and diABZI were encapsulated in LNPs and used at 10 nmol per mouse hereafter. d , Mice were immunized with diABZI + OVA or ABM5–OVA on days 0 and 14. OVA-tetramer + CD8 + T cells in PBMCs were analysed on day 21. From left to right, n = 4, 4 and 6 mice. e , WT or STING −/− mice were immunized and analysed as in panel d . n = 4 mice. f , g , Mice were immunized with ABM5–OVA, or OVA peptide with or without 10 μg of <t>ODN1018,</t> ISCOMs or poly-I:C on days 0, 14 ( f ) and 28 ( g ). n = 5 mice. h , Mice were immunized with ABM5–OVA, diABZI + OVA or ABD–S–OVA for three doses. n = 5 mice. i , WT or Batf3 −/− mice were immunized as in panel d . n = 4 mice. j , k , Mice were immunized as in panel d , challenged with 2 × 10 5 B16-OVA on day 28. From the top, n = 7, 8 and 8 mice. l – o , Mice were inoculated with 2 × 10 5 B16-OVA ( l , m ) or 5 × 10 5 E.G7-OVA ( n , o ), and received diABZI + OVA or ABM5–OVA on days 4, 11 and 18. B16-OVA. From the top, n = 8, 8 and 9 mice. E.G7-OVA n = 12 mice. p , Mice were immunized as in panel d , and challenged intravenously by 2 × 10 5 B16-OVA on day 28. Metastatic foci in the lungs were counted on day 46. n = 5 mice. Data are mean ± s.e.m. One-way ANOVA with Tukey’s multiple comparisons test ( a – i , p ), two-way ANOVA ( j , l , n ) and the log-rank test ( k , m , o ) were used. Data are representative of two independent experiments.
Odn1018, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/odn+1018/ODN+1018+sodium/pmc12043507-370-25-27
Average 93 stars, based on 1 article reviews
odn1018 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
odn 1018 vaccigrade  (InvivoGen)
N/A
CpG ODN, Class B (human/mouse) - TLR9 agonist
   Buy from Supplier
toll-like receptor 9 (tlr-9) oligonucleotide agonist, cpg (odn-1018)  (TriLink)
90
TriLink toll-like receptor 9 (tlr-9) oligonucleotide agonist, cpg (odn-1018)
a , BMDCs were incubated with 100 nM OVA peptide, diABZI + OVA or ABM5–OVA either carrier free or encapsulated in LNPs for 4 h. n = 3 biologically independent samples. b , c , BMDCs receiving 50 nM OVA peptide, ABM5–OVA or LNP-encapsulated ABM5–OVA for 4 h and then co-cultured with OT-I cells for 72 h. n = 3 biologically independent samples. All ABM5–OVA, ABD–S–OVA, OVA peptides and diABZI were encapsulated in LNPs and used at 10 nmol per mouse hereafter. d , Mice were immunized with diABZI + OVA or ABM5–OVA on days 0 and 14. OVA-tetramer + CD8 + T cells in PBMCs were analysed on day 21. From left to right, n = 4, 4 and 6 mice. e , WT or STING −/− mice were immunized and analysed as in panel d . n = 4 mice. f , g , Mice were immunized with ABM5–OVA, or OVA peptide with or without 10 μg of <t>ODN1018,</t> ISCOMs or poly-I:C on days 0, 14 ( f ) and 28 ( g ). n = 5 mice. h , Mice were immunized with ABM5–OVA, diABZI + OVA or ABD–S–OVA for three doses. n = 5 mice. i , WT or Batf3 −/− mice were immunized as in panel d . n = 4 mice. j , k , Mice were immunized as in panel d , challenged with 2 × 10 5 B16-OVA on day 28. From the top, n = 7, 8 and 8 mice. l – o , Mice were inoculated with 2 × 10 5 B16-OVA ( l , m ) or 5 × 10 5 E.G7-OVA ( n , o ), and received diABZI + OVA or ABM5–OVA on days 4, 11 and 18. B16-OVA. From the top, n = 8, 8 and 9 mice. E.G7-OVA n = 12 mice. p , Mice were immunized as in panel d , and challenged intravenously by 2 × 10 5 B16-OVA on day 28. Metastatic foci in the lungs were counted on day 46. n = 5 mice. Data are mean ± s.e.m. One-way ANOVA with Tukey’s multiple comparisons test ( a – i , p ), two-way ANOVA ( j , l , n ) and the log-rank test ( k , m , o ) were used. Data are representative of two independent experiments.
Toll Like Receptor 9 (Tlr 9) Oligonucleotide Agonist, Cpg (Odn 1018), supplied by TriLink, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/odn+1018/toll+like+receptor+9++tlr+9++oligonucleotide+agonist++cpg++odn+1018+/pmc10051918-50-38-40
Average 90 stars, based on 1 article reviews
toll-like receptor 9 (tlr-9) oligonucleotide agonist, cpg (odn-1018) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
lps-free 1018 cpg-odn  (TriLink)
90
TriLink lps-free 1018 cpg-odn
a , BMDCs were incubated with 100 nM OVA peptide, diABZI + OVA or ABM5–OVA either carrier free or encapsulated in LNPs for 4 h. n = 3 biologically independent samples. b , c , BMDCs receiving 50 nM OVA peptide, ABM5–OVA or LNP-encapsulated ABM5–OVA for 4 h and then co-cultured with OT-I cells for 72 h. n = 3 biologically independent samples. All ABM5–OVA, ABD–S–OVA, OVA peptides and diABZI were encapsulated in LNPs and used at 10 nmol per mouse hereafter. d , Mice were immunized with diABZI + OVA or ABM5–OVA on days 0 and 14. OVA-tetramer + CD8 + T cells in PBMCs were analysed on day 21. From left to right, n = 4, 4 and 6 mice. e , WT or STING −/− mice were immunized and analysed as in panel d . n = 4 mice. f , g , Mice were immunized with ABM5–OVA, or OVA peptide with or without 10 μg of <t>ODN1018,</t> ISCOMs or poly-I:C on days 0, 14 ( f ) and 28 ( g ). n = 5 mice. h , Mice were immunized with ABM5–OVA, diABZI + OVA or ABD–S–OVA for three doses. n = 5 mice. i , WT or Batf3 −/− mice were immunized as in panel d . n = 4 mice. j , k , Mice were immunized as in panel d , challenged with 2 × 10 5 B16-OVA on day 28. From the top, n = 7, 8 and 8 mice. l – o , Mice were inoculated with 2 × 10 5 B16-OVA ( l , m ) or 5 × 10 5 E.G7-OVA ( n , o ), and received diABZI + OVA or ABM5–OVA on days 4, 11 and 18. B16-OVA. From the top, n = 8, 8 and 9 mice. E.G7-OVA n = 12 mice. p , Mice were immunized as in panel d , and challenged intravenously by 2 × 10 5 B16-OVA on day 28. Metastatic foci in the lungs were counted on day 46. n = 5 mice. Data are mean ± s.e.m. One-way ANOVA with Tukey’s multiple comparisons test ( a – i , p ), two-way ANOVA ( j , l , n ) and the log-rank test ( k , m , o ) were used. Data are representative of two independent experiments.
Lps Free 1018 Cpg Odn, supplied by TriLink, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/odn+1018/lps+free+1018+cpg+odn/pm25269705-185-0-8
Average 90 stars, based on 1 article reviews
lps-free 1018 cpg-odn - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
tlr9 agonist 166  (MedChemExpress)
94
MedChemExpress tlr9 agonist 166
a , BMDCs were incubated with 100 nM OVA peptide, diABZI + OVA or ABM5–OVA either carrier free or encapsulated in LNPs for 4 h. n = 3 biologically independent samples. b , c , BMDCs receiving 50 nM OVA peptide, ABM5–OVA or LNP-encapsulated ABM5–OVA for 4 h and then co-cultured with OT-I cells for 72 h. n = 3 biologically independent samples. All ABM5–OVA, ABD–S–OVA, OVA peptides and diABZI were encapsulated in LNPs and used at 10 nmol per mouse hereafter. d , Mice were immunized with diABZI + OVA or ABM5–OVA on days 0 and 14. OVA-tetramer + CD8 + T cells in PBMCs were analysed on day 21. From left to right, n = 4, 4 and 6 mice. e , WT or STING −/− mice were immunized and analysed as in panel d . n = 4 mice. f , g , Mice were immunized with ABM5–OVA, or OVA peptide with or without 10 μg of <t>ODN1018,</t> ISCOMs or poly-I:C on days 0, 14 ( f ) and 28 ( g ). n = 5 mice. h , Mice were immunized with ABM5–OVA, diABZI + OVA or ABD–S–OVA for three doses. n = 5 mice. i , WT or Batf3 −/− mice were immunized as in panel d . n = 4 mice. j , k , Mice were immunized as in panel d , challenged with 2 × 10 5 B16-OVA on day 28. From the top, n = 7, 8 and 8 mice. l – o , Mice were inoculated with 2 × 10 5 B16-OVA ( l , m ) or 5 × 10 5 E.G7-OVA ( n , o ), and received diABZI + OVA or ABM5–OVA on days 4, 11 and 18. B16-OVA. From the top, n = 8, 8 and 9 mice. E.G7-OVA n = 12 mice. p , Mice were immunized as in panel d , and challenged intravenously by 2 × 10 5 B16-OVA on day 28. Metastatic foci in the lungs were counted on day 46. n = 5 mice. Data are mean ± s.e.m. One-way ANOVA with Tukey’s multiple comparisons test ( a – i , p ), two-way ANOVA ( j , l , n ) and the log-rank test ( k , m , o ) were used. Data are representative of two independent experiments.
Tlr9 Agonist 166, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/odn+1018/ODN+1018/pm41791624-84-0-9
Average 94 stars, based on 1 article reviews
tlr9 agonist 166 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
odn 1018  (TargetMol)
N/A
   Buy from Supplier
biotin-labeled odn 1018 sodium  (TargetMol)
N/A
   Buy from Supplier
odn 1018  (Aladdin Scientific Corporation)
N/A
ODN 1018 (1018 ISS; CpG 1018), an oligodeoxynucleotide, is a TLR-9 agonist. ODN 1018 is also a synthetic immunostimulatory sequence that can be used as vaccine adjuvant. Sequence: 5′-TGACTGTGAACGTTCGAGATGA-3′Form:SolidIC50& Target:TLR9
   Buy from Supplier
fitc-labeled odn 1018 sodium  (TargetMol)
N/A
   Buy from Supplier
fitc-labeled odn 1018 sodium  (MedChemExpress)
N/A
FITC-labeled ODN 1018 (sodium),an oligodeoxynucleotide, is a TLR-9 agonist. FITC-labeled ODN 1018 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or
   Buy from Supplier

Image Search Results


a , BMDCs were incubated with 100 nM OVA peptide, diABZI + OVA or ABM5–OVA either carrier free or encapsulated in LNPs for 4 h. n = 3 biologically independent samples. b , c , BMDCs receiving 50 nM OVA peptide, ABM5–OVA or LNP-encapsulated ABM5–OVA for 4 h and then co-cultured with OT-I cells for 72 h. n = 3 biologically independent samples. All ABM5–OVA, ABD–S–OVA, OVA peptides and diABZI were encapsulated in LNPs and used at 10 nmol per mouse hereafter. d , Mice were immunized with diABZI + OVA or ABM5–OVA on days 0 and 14. OVA-tetramer + CD8 + T cells in PBMCs were analysed on day 21. From left to right, n = 4, 4 and 6 mice. e , WT or STING −/− mice were immunized and analysed as in panel d . n = 4 mice. f , g , Mice were immunized with ABM5–OVA, or OVA peptide with or without 10 μg of ODN1018, ISCOMs or poly-I:C on days 0, 14 ( f ) and 28 ( g ). n = 5 mice. h , Mice were immunized with ABM5–OVA, diABZI + OVA or ABD–S–OVA for three doses. n = 5 mice. i , WT or Batf3 −/− mice were immunized as in panel d . n = 4 mice. j , k , Mice were immunized as in panel d , challenged with 2 × 10 5 B16-OVA on day 28. From the top, n = 7, 8 and 8 mice. l – o , Mice were inoculated with 2 × 10 5 B16-OVA ( l , m ) or 5 × 10 5 E.G7-OVA ( n , o ), and received diABZI + OVA or ABM5–OVA on days 4, 11 and 18. B16-OVA. From the top, n = 8, 8 and 9 mice. E.G7-OVA n = 12 mice. p , Mice were immunized as in panel d , and challenged intravenously by 2 × 10 5 B16-OVA on day 28. Metastatic foci in the lungs were counted on day 46. n = 5 mice. Data are mean ± s.e.m. One-way ANOVA with Tukey’s multiple comparisons test ( a – i , p ), two-way ANOVA ( j , l , n ) and the log-rank test ( k , m , o ) were used. Data are representative of two independent experiments.

Journal: Nature

Article Title: STING agonist-based ER-targeting molecules boost antigen cross-presentation

doi: 10.1038/s41586-025-08758-w

Figure Lengend Snippet: a , BMDCs were incubated with 100 nM OVA peptide, diABZI + OVA or ABM5–OVA either carrier free or encapsulated in LNPs for 4 h. n = 3 biologically independent samples. b , c , BMDCs receiving 50 nM OVA peptide, ABM5–OVA or LNP-encapsulated ABM5–OVA for 4 h and then co-cultured with OT-I cells for 72 h. n = 3 biologically independent samples. All ABM5–OVA, ABD–S–OVA, OVA peptides and diABZI were encapsulated in LNPs and used at 10 nmol per mouse hereafter. d , Mice were immunized with diABZI + OVA or ABM5–OVA on days 0 and 14. OVA-tetramer + CD8 + T cells in PBMCs were analysed on day 21. From left to right, n = 4, 4 and 6 mice. e , WT or STING −/− mice were immunized and analysed as in panel d . n = 4 mice. f , g , Mice were immunized with ABM5–OVA, or OVA peptide with or without 10 μg of ODN1018, ISCOMs or poly-I:C on days 0, 14 ( f ) and 28 ( g ). n = 5 mice. h , Mice were immunized with ABM5–OVA, diABZI + OVA or ABD–S–OVA for three doses. n = 5 mice. i , WT or Batf3 −/− mice were immunized as in panel d . n = 4 mice. j , k , Mice were immunized as in panel d , challenged with 2 × 10 5 B16-OVA on day 28. From the top, n = 7, 8 and 8 mice. l – o , Mice were inoculated with 2 × 10 5 B16-OVA ( l , m ) or 5 × 10 5 E.G7-OVA ( n , o ), and received diABZI + OVA or ABM5–OVA on days 4, 11 and 18. B16-OVA. From the top, n = 8, 8 and 9 mice. E.G7-OVA n = 12 mice. p , Mice were immunized as in panel d , and challenged intravenously by 2 × 10 5 B16-OVA on day 28. Metastatic foci in the lungs were counted on day 46. n = 5 mice. Data are mean ± s.e.m. One-way ANOVA with Tukey’s multiple comparisons test ( a – i , p ), two-way ANOVA ( j , l , n ) and the log-rank test ( k , m , o ) were used. Data are representative of two independent experiments.

Article Snippet: C57BL/6 mice, 6–8 weeks old, were subcutaneously immunized with various free or LNP-encapsulated peptides, with or without free or LNP-encapsulated diABZI, free poly-I:C (tlrl-pic, InvivoGen), ODN1018 (HY-150724C, MCE) or ISCOMs, serving as controls or benchmarks.

Techniques: Incubation, Cell Culture